Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NagPet is a veterinary antimicrobial suspension developed by Bionag, utilizing silver nanoparticles (AgNPs) as the active therapeutic agent. It is designed for the treatment of a broad spectrum of systemic and localized infections in companion animals, including dogs and cats. The silver nanoparticles exert their effect through multiple mechanisms: they release silver ions that disrupt microbial cell membranes, generate reactive oxygen species (ROS) leading to oxidative stress, and bind to microbial DNA and proteins to inhibit replication and metabolic functions. NagPet is indicated for severe viral conditions such as Canine Parvovirus and Feline Panleukopenia, as well as systemic bacterial and fungal infections, respiratory complexes, and various dermatological conditions and wounds.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NagPet.